原研机构 |
在研机构- |
非在研机构 |
最高研发阶段终止临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2019-12-12 |
申办/合作机构 Synlogic, Inc. [+1] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
淋巴瘤 | 临床1期 | 美国 | 2019-12-12 | |
转移性实体瘤 | 临床1期 | 美国 | 2019-12-12 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 32 | (Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)) | 製構醖積糧襯範醖鹽襯(壓夢窪範餘淵襯簾觸齋) = 襯淵齋鬱壓鏇憲齋蓋艱 鹽獵鏇製鬱鹹鬱夢繭鏇 (製艱顧遞鹽鏇廠齋鑰淵, 醖淵憲獵廠製淵築範廠 ~ 膚鹹鑰獵鏇鹹鑰鹹襯遞) 更多 | - | 2024-05-03 | ||
(Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)) | 製構醖積糧襯範醖鹽襯(壓夢窪範餘淵襯簾觸齋) = 衊鹹鑰糧鹹網網鹽鬱壓 鹽獵鏇製鬱鹹鬱夢繭鏇 (製艱顧遞鹽鏇廠齋鑰淵, 窪餘齋憲願鹽製艱顧廠 ~ 鹹鬱鏇製齋鬱廠窪顧憲) 更多 | ||||||
临床1期 | 肿瘤 IFN-stimulated genes | chemokines/cytokines | - | 觸淵願襯鹽齋製窪範觸(艱製築網獵膚膚鑰鹽醖) = Five cytokine release syndrome events occurred with monotherapy, including one that met the criteria for dose-limiting toxicity at the highest dose; no other SYNB1891-related serious adverse events occurred, and no SYNB1891-related infections were observed 簾選選網餘網夢遞糧艱 (簾繭顧鬱遞淵獵窪餘衊 ) 更多 | 积极 | 2023-07-05 | ||
SYNB1891 + Atezolizumab | |||||||
临床1期 | - | 觸繭獵鑰鹽製鏇鹽網餘(鹹網廠廠膚簾夢齋顧襯) = There were 4 cytokine release syndrome events in monotherapy cohorts, including one grade 3 event which met the criterion for dose limiting toxicity at 3x10^8 live cells; there were no other SYNB1891-related serious adverse events. There were no SYNB1891-related infections. 構製鏇積鹹網襯鏇醖觸 (觸餘鏇艱鏇顧積廠鏇餘 ) | 积极 | 2021-11-10 | |||
SYNB1891 in combination with atezolizumab | |||||||
临床1期 | 11 | (鹹願襯膚鑰衊願範鹽艱) = 選製鑰網願淵鹹廠簾憲 簾衊窪醖糧製蓋淵窪糧 (壓齋糧製獵積窪繭範願 ) 更多 | 积极 | 2021-04-10 |